---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020023"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:31:33.335516+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Novavax issues 2025 financial guidance and strategic update at TD Cowen conference

## Summary
- Provided 2025 revenue framework and combined R&D/SG&A expense guidance for 2025 and 2026.
- Reaffirmed transition of COVID-19 vaccine commercialization to Sanofi starting 2025-2026 season.
- Highlighted clinical progress on COVID-19, CIC, and standalone flu vaccine candidates.

## SEC filing metadata
- accession: 0001104659-25-020023
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925020023/0001104659-25-020023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925020023/tm258153d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020023
- JSON: https://secwatch.observer/filing/0001104659-25-020023.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.